GBC-Atrial SA

The Atrial project is dedicated to the pursuit of the clinical development of a promising novel therapeutic (GBC-A1) in atrial fibrillation (AF), the most common serious abnormal heart rhythm, which affects 2 to 3% of the population in Europe and North America.

GBC-Atrial has obtained an exclusive world-wide license relating to the clinical development of this asset. Furthermore, GBC-A1 has already been in clinical development in another indication up to phase IIa (proof-of-concept), and displayed a remarkable tolerability and safety profile. GBC-A1 was recently the subject of a phase Ia clinical trial financed by GBC-Atrial to determine the suitability of this molecule in a cardiac setting: not only was GBC-A1 was very well tolerated, but it also displayed the first signs of efficacy in a cardiac setting.

The pursuit of this development plan involves a more extended single ascending dose study, followed by a multiple ascending dose, a small food-effect study, and an cardiac electrophysiology study to fully de-risk the subsequent phase II studies. Two phase II studies are planned, a proof-of-concept study, and a full-blown phase IIb study on atrial fibrillation patients.

GBC-Atrial is looking for partners to finance the remainder of the phase I and phase II parts of the clinical development pipeline. The partners would enter into the ownership of the GBC-Atrial SA at very favorable terms. We are also open to other co-development possibilities with pharmaceutical company partners.


See also the website of GBC-HpVac SA

The HpVac project is based on two scientific observations:

  1. The gastrointestinal (GI) microbiota interacts with and modifies its human host.
  2. The increasing prevalence of allergic diseases in humans, especially children, can be partially explained by a reduction in the exposure of the immune system to external stimuli due to lifestyle changes and the extensive use of antibiotics (“hygiene hypothesis”). A reduction in the diversity of the gastrointestinal microbiota is linked to many early-onset diseases, including atopy, asthma and hay fever.

A protein produced by a bacterium living in the GI tract of 50% of humans has been shown to modulate the human immune system, with the main purpose of allowing this bacterium to perennially colonize the human GI, and avoid being cleared by the host immune system. However, this protein would also appear to provide protection against a number of allergic diseases, including asthma, atopic dermatitis and hay fever.

The HpVac project proposes the development this protein as a treatment against these wide-spread diseases. The protein has already demonstrated its tolerability in humans (humans have harbored this bacterium for thousands of years), and its therapeutic effect (epidemiological studies on the incidence of allergic diseases in humans with or without the bacterium). If successful, a treatment based on this protein would revolutionize the treatment of allergic diseases, and represent the first significant disease-modifying treatment in years.